Adoption of Multi-class Fixed Dose Combination Once-daily Single Tablet HIV Regimen in Europe

Once-daily multi-class fixed dose combination (FDC) once-daily single tablet regimen (STR) is critical part of antiretroviral treatment armamentarium to manage patients with human immunodeficiency virus (HIV). Multi-wave retrospective medical chart reviews of HIV patients were conducted in Europe (5EU: UK/France/Germany/Italy/Spain) between 1Q2009 and 1Q2015 among patients initiating or switching HIV regimen. Over 1Q2009-1Q2015, 200 physicians abstracted an average of 3000 patient charts per quarter. STR prescribing trends increased in 5EU over the years: 1Q200917%, 1Q2010/1Q2011-23%, 1Q2012-24%, 1Q2013-30%, 1Q2014-44%, 1Q2015-53%. The top reasons for switching from conventional antiretroviral regimen dosing to an STR in 1Q2009/1Q2015 were simplification (74%/64%), tolerability (14%/19%), and patient decision (12%/18%). These observed trends may emphasize the importance HIV providers have given towards maintaining HIV patients on a simple and yet tolerable regimen with the hope to achieve optimal adherence and clinical outcomes over the longer term.